AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioAffinity Technologies Q3 revenue up 86% YoY, CyPath Lung sales at record high.
ByAinvest
Friday, Nov 14, 2025 8:35 am ET1min read
• bioAffinity Technologies reports 86% YoY increase in CyPath Lung testing revenue • Sales reach record high in Q3 2025, a 92% increase from Q2 • Growth driven by VA hospital adoption and market expansion • Focus on noninvasive lung cancer detection and other lung diseases • Strong balance sheet position • Company focused on providing accurate early-stage lung cancer detection • BioAffinity Technologies a biotechnology company • Nasdaq-listed under BIAF and BIAFW • San Antonio-based company • Q3 2025 financial results announced on November 14, 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet